Efficacy and Safety Evaluation of Budoprutug (TNT119) in Patients with Systemic Lupus Erythematosus

The primary objective of this study is to evaluate the **efficacy** and **safety** of budoprutug (TNT119) in participants diagnosed with **Systemic Lupus Erythematosus**. This is clinically relevant as it aims to determine the potential therapeutic benefits and adverse effects of budoprutug, which could contribute to improved management of this chronic autoimmune disease. No secondary objectives are provided in the available data.

The clinical trial involves a total of **13 participants** diagnosed with **Systemic Lupus Erythematosus**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected without targeting any vulnerable populations. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion criteria. The selection process for the trial population was not disclosed.

The clinical trial is designed to evaluate the efficacy and safety of **budoprutug** (TNT119) in participants diagnosed with **Systemic Lupus Erythematosus**. This study is structured as a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is July 1, 2025, with an anticipated completion date of July 31, 2027. The trial will involve multiple study visits, beginning with an inclusion visit, which serves as a screening to determine participant eligibility based on predefined criteria. Following successful inclusion, participants will undergo a series of follow-up visits at regular intervals to monitor their response to the treatment and assess any adverse effects. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the treatment's impact.

The expected duration of participant involvement in the trial is approximately two years, contingent upon adherence to the study protocol and absence of any conditions necessitating early termination. Conditions that may lead to early withdrawal include significant adverse reactions, non-compliance with study procedures, or any medical condition that, in the investigator's judgment, warrants discontinuation for the participant's safety. Throughout the trial, data will be collected and analyzed to determine the primary and secondary endpoints, although specific endpoints are not detailed in the available data. The trial's methodology ensures rigorous evaluation of the investigational product's therapeutic potential while maintaining participant safety and data integrity.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided dataset. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on July 1, 2025, with an estimated completion date of July 31, 2027. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for assessment, are not specified in the available information. The trial's focus on efficacy is aligned with its categorization as a Phase 3 study, which typically involves a larger participant population to confirm effectiveness and monitor side effects.